Interview: Janssen R&D head Hait explains J&J's new platforms
This article was originally published in Scrip
Executive Summary
Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has three new platforms that it's integrating into its existing therapeutic areas to shift the focus of R&D from disease treatment to prevention, according to global head of Janssen R&D William Hait.